Patent ID: 11970491
Assignee: AUCENTRA THERAPEUTICS PTY LTD
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 12:
13. A method according to claim 12, wherein the additional agent(s) is selected from one or more of the following categories of anti-cancer agents; alkylating agents; antimetabolite agents; antitumour antibiotics; antimitotic agents; and topoisomerase inhibitors; anti-oestrogens; antiandrogens; LHRH antagonists and agonists; progestogens; aromatase inhibitors; and inhibitors of 5α-reductase; c-Src kinase family inhibitors; metalloproteinase inhibitors; inhibitors of urokinase plasminogen activator receptor function; and antibodies to heparanase; inhibitors of growth factor function; tyrosine kinase inhibitors; inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family; inhibitors of serine/threonine kinases; inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase inhibitors, phosphoinositide-3-kinase (PI3K) inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; aurora kinase inhibitors; and cyclin dependent kinase inhibitors; antiangiogenic agents; vascular damaging agents; and endothelin receptor antagonists.